Compare iShares MSCI Germany (DAX) (EWG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Sanofi SA — how do they compare? iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 67× iShares MSCI Germany (DAX)'s market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Sanofi SA for 94 Days on average.
| EWG | SNY | |
|---|---|---|
Market Cap | $1.42B | $95.18B |
Volume | 1,110,573 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $52.34 |
52-Week Low | $38.08 | $39.51 |
Typical Hold Time | 54 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $40.96 with minimal daily movement (+0.12%). Technical indicators show a bearish trend with strong selling pressure across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The stock faces resistance at $41 with support at $40. Recent European market news highlights mixed sentiment with resilient equities but concerns about ECB rate hikes and energy-driven inflation pressures.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from potential ECB tightening. Investment opportunity exists if oversold RSI levels trigger a rebound, but risks include further rate hikes and energy price volatility. Stock performance hinges on European economic stability and inflation control.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
